Stanley Fineman, MD
Allergy & Immunology · Marietta, GANPI 1386684207
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (48.0%), grants and consulting fees — rather than concentrated in one kind of arrangement. 28 manufacturers reported payments, led by Sanofi at 39.5% of the total. Reporting peaked in 2021 at $41,410 and has fallen 50.9% since, to $20,342 in 2025. Among allergy & immunology clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 529 payments — averaging $352.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$74K
- Shire North American Group Inc$25K
- Takeda Pharmaceuticals U.S.A., Inc.$19K
- Genentech USA, Inc.$18K
- Biocryst US Sales Co., LLC$13K
- Pharming Healthcare, Inc.$7K
- plus $31K from 22 others
Across 103 payments — averaging $6494.05 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Aimmune Therapeutics, Inc.$369K
- Novartis$178K
- Regeneron$95K
- Biocryst Pharmaceuticals, Inc.$24K
- Alk-abello, Inc$3K
What the payments were for
- Consulting fees$33,23618%
- Speaking & faculty fees$89,45148%
- Grants$49,00026%
- Travel & lodging$3,9142%
- Food & beverage$10,6116%
- Education$150%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 30 | $73,558 |
| Shire North American Group Inc | 26 | $24,750 |
| Takeda Pharmaceuticals U.S.A., Inc. | 56 | $19,410 |
| Genentech USA, Inc. | 30 | $18,247 |
| Biocryst US Sales Co., LLC | 35 | $12,557 |
| Pharming Healthcare, Inc. | 12 | $7,185 |
| Novartis | 38 | $5,440 |
| Teva Pharmaceuticals USA, Inc. | 17 | $5,360 |
| Biocryst Pharmaceuticals, Inc. | 9 | $5,176 |
| Regeneron | 2 | $3,936 |
| Aimmune Therapeutics, Inc. | 4 | $3,705 |
| CSL Behring | 55 | $1,362 |
| AstraZeneca | 36 | $1,084 |
| Optinose US, Inc. | 12 | $993 |
| Regeneron Healthcare Solutions, Inc. | 38 | $818 |
| GSK | 43 | $550 |
| Alk-abello, Inc | 4 | $374 |
| Kaleo, Inc. | 18 | $337 |
| Covis Pharma GmbH | 13 | $261 |
| Pfizer | 13 | $248 |
| Grifols USA, LLC | 11 | $212 |
| Boehringer Ingelheim | 10 | $194 |
| Octapharma USA, Inc. | 3 | $177 |
| Amgen(2 entities) | 7 | $146 |
| Blueprint Medicines Corporation | 2 | $63 |
| Merck | 2 | $34 |
| AbbVie | 2 | $27 |
| ADMA Biomanufacturing LLC | 1 | $23 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$186,226 in reported general payments places this provider in the 95th percentile of 107 allergy & immunology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Breo ElliptaFluticasone/Vilanterol | 36 | $17,245 |
| Azelastine Hcl | 12 | $541 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 14 | $468 |
| Ipratropium Bromide | 14 | $371 |
| Montelukast Sodium | 28 | $233 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKBreo Ellipta | $550 | $17,24536 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 107 allergy & immunology providers in Georgia.
Other allergy & immunology in Marietta
- Grace ChiangMarietta$5K
- Michael BlaissRoswell$1.1M
- Deborah BirxAtlanta$470K
- Tracy BridgesAlbany$364K
- Jack EadesMacon$237K
- Robert CartwrightColumbus$169K
- Robert ChrzanowskiColumbus$115K
- Belinda GrahamSmyrna$94K
- Lily HwangRoswell$88K
- Paul RabinowitzAtlanta$57K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.